Literature DB >> 3097699

Discriminative stimulus properties of the serotonin agonist MK 212.

K A Cunningham, P M Callahan, J B Appel.   

Abstract

In an attempt to clarify the role of 5-hydroxytryptamine (5-HT) in the discriminative stimulus properties of MK 212 (6-chloro-2[1-piperazinyl]pyrazine), male Sprague-Dawley rats were trained to discriminate 0.5 mg/kg of this compound from saline. While the putative 5-HT agonists fenfluramine and m-chlorophenylpiperazine (MCPP) mimicked MK 212 in a dose-related manner, d-lysergic acid diethylamide (LSD), 8-hydroxy-2(di-n-propylamino)tetralin (8-OHDPAT), 5-methoxy-N,N-dimethyltryptamine (5-MeODMT), quipazine, Ru 24969, and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) failed to substitute completely. The 5-HT1/5-HT2 antagonists BC 105, metergoline, and methysergide completely blocked the MK 212 cue, while the selective 5-HT2 antagonists ketanserin and pirenperone, the dopamine antagonists haloperidol and spiperone, and the beta-noradrenergic antagonist propranolol were without effect. The substitutions of fenfluramine and MCPP for MK 212 support a role for 5-HT in the MK 212 cue; however, the lack of substitution of many other 5-HT agonists is difficult to explain. The complete antagonism by 5-HT1/5-HT2 but not by selective 5-HT2, antagonists suggests the possibility that 5-HT1 receptors mediate the stimulus properties of MK 212. Further research is needed to support this hypothesis and to investigate the relative role of 5-HT and other neurotransmitters in the stimulus effects of MK 212.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3097699     DOI: 10.1007/bf00181240

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Behaviorally induced sensitivity to the discriminable properties of LSD.

Authors:  I Greenberg; D M Kuhn; J B Appel
Journal:  Psychopharmacologia       Date:  1975-09-17

2.  Similarities between the pharmacological actions of quipazine and serotonin.

Authors:  E Hong; L F Sancilio; R Vargas; E G Pardo
Journal:  Eur J Pharmacol       Date:  1969       Impact factor: 4.432

3.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats.

Authors:  R W Fuller; H D Snoddy; N R Mason; J E Owen
Journal:  Neuropharmacology       Date:  1981-02       Impact factor: 5.250

4.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

5.  A neuropharmacological analysis of the discriminative stimulus properties of fenfluramine.

Authors:  F J White; J B Appel
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Effect of 1-(m-trifluoromethylphenyl)-piperazine on 3H-serotonin binding to membranes from rat brain in vitro and on serotonin turnover in rat brain in vivo.

Authors:  R W Fuller; H D Snoddy; N R Mason; B R Molloy
Journal:  Eur J Pharmacol       Date:  1978-11-01       Impact factor: 4.432

7.  Behavioral effects of 5-methoxy-N,N-dimethyltryptamine and dose-dependent antagonism by BC-105.

Authors:  R Young; J A Rosecrans; R A Glennon
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

8.  Biochemical assessment of the central 5-HT agonist activity of RU 24969 (a piperidinyl indole).

Authors:  C Euvrard; J R Boissier
Journal:  Eur J Pharmacol       Date:  1980-04-11       Impact factor: 4.432

9.  Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD.

Authors:  K A Cunningham; P M Callahan; J B Appel
Journal:  Eur J Pharmacol       Date:  1985-01-22       Impact factor: 4.432

10.  A comparative electrophysiological and biochemical assessment of serotonin (5-HT) and a novel 5-HT agonist (MK-212) on central serotonergic receptors.

Authors:  G G Yarbrough; D K Singh; D J Pettibone
Journal:  Neuropharmacology       Date:  1984-11       Impact factor: 5.250

View more
  7 in total

1.  Discriminative stimulus effects of serotonin agonists, neutral antagonists, and inverse agonists in pigeons: perspectives on intrinsic efficacy measurements in vivo.

Authors:  Martilias Farrell; Sharon Rosenzweig-Lipson; Ellen Walker
Journal:  Psychopharmacology (Berl)       Date:  2010-06-05       Impact factor: 4.530

2.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze.

Authors:  Antonio Pedro de Mello Cruz; Gilson Pinheiro; Sérgio Henrique Alves; Graziela Ferreira; Marília Mendes; Letícia Faria; Carlos Eduardo Macedo; Vitor Motta; J Landeira-Fernandez
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

4.  Selective reduction by serotonergic agents of hypertonic saline consumption in rats: evidence for possible 5-HT1C receptor mediation.

Authors:  J C Neill; S J Cooper
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method.

Authors:  Atheir I Abbas; Daniel J Urban; Niels H Jensen; Martilias S Farrell; Wesley K Kroeze; Piotr Mieczkowski; Zefeng Wang; Bryan L Roth
Journal:  Nucleic Acids Res       Date:  2010-02-25       Impact factor: 16.971

6.  Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives.

Authors:  D Fiorella; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

7.  In vivo Schild regression analyses using nonselective 5-HT2C receptor antagonists in a rat operant behavioral assay.

Authors:  Ellen A Walker; Edward K Brown; Steven N Sterious
Journal:  Psychopharmacology (Berl)       Date:  2007-04-01       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.